Papers by Despina Selalmatzidou
Endocrine, Feb 8, 2014
Several studies have shown that acromegaly is associated with increased psychological morbidity. ... more Several studies have shown that acromegaly is associated with increased psychological morbidity. However, it is not known whether this is attributed to acromegaly per se or to its chronicity as a debilitating disease affecting quality of life (QoL). The aim of this study was to assess psychological profile in acromegalics compared with those suffering from other serious chronic diseases and healthy controls. Secondary end points were QoL assessment and its association with mood disturbances. Comparative, cross-sectional study conducted in Northern Greece (2011-2012). The Greek versions of the Profile of Mood States (POMS) and AcroQoL questionnaires were used to assess psychological status and QoL, respectively. Forty acromegalics, 40 age- and sex-matched people with other chronic diseases and 80 healthy controls were included. No significant differences were identified between acromegalics and those suffering from other chronic diseases, regarding tension, anger, depression, confusion, fatigue and vigor. Compared with healthy controls, acromegalics suffered more from depression and anger, which remained significant after controlling for age, gender and marital status (p = 0.003 and p = 0.048, respectively). Negative predictors were female gender, macroadenomas and radiotherapy. AcroQoL scores were negatively associated with POMS subscales. Males had better QoL than females. Other than a negative association between AcroQoL-relationships subscale and disease duration, no association with other parameters was observed. Acromegaly has a negative impact on psychological status, which is worse than that of general population, but comparable to other chronic diseases. Mood disturbances are associated with impaired QoL, mainly in females and those with longer disease duration.
International Journal of Clinical Practice, 2014
Subclinical hypothyroidism (SH) is associated with increased risk for atherosclerosis, mainly att... more Subclinical hypothyroidism (SH) is associated with increased risk for atherosclerosis, mainly attributable to dyslipidaemia and hypercoagulability. However, conflicting data exist regarding the effect of L-thyroxine substitution on these parameters.The purpose of this study was to assess the effect of L-thyroxine therapy on lipidaemic profile, coagulation markers, high-sensitivity C-reactive protein (hsCRP) and glucose homoeostasis in SH patients. Methods: It was a prospective open-label study. The following parameters were measured before and 6 months after intervention: anthropometric data, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoproteins B (apoB) and A1 (apoA1), lipoprotein (a) [Lp(a)], fasting plasma glucose and insulin, homoeostasis model assessment-insulin resistance (HOMA-IR), hsCRP, antithrombin III (AT-III), protein C (PC), protein S (PS), fibrinogen and homocysteine. Results: Thirty-two patients (30 women) aged 52.1 AE 13.9 years with SH completed the study. Baseline mean TSH levels were 6.79 AE 2.58 mIU/ml. Achievement of euthyroidism significantly reduced systolic blood pressure (BP) in patients with SH (from 135.2 AE 18.5 to 129.7 AE 15.8 mmHg, p = 0.03) and diastolic BP only in those with baseline TSH levels > 7 mIU/ml (from 79.5 AE 9.8 to 72.1 AE 7.3 mmHg, p = 0.03).No significant changes in body weight, TC, LDL-C, HDL-C, TG, apoB, glucose, insulin, HOMA-IR, hsCRP, AT-III, PC, PS, fibrinogen or homocysteine levels were noticed after restoration of euthyroidism, except for a decrease in apoA1 (p = 0.04) and an increase in Lp(a) levels (p = 0.02). Conclusions: Except for a reduction in systolic and diastolic BP, thyroid substitution therapy does not affect lipidaemic profile, systematic inflammation, glucose homoeostasis or coagulation in patients with SH. What's known • Several studies link subclinical hypothyroidism (SH) to increased cardiovascular risk mainly because of the increased prevalence of atherosclerotic risk factors (dyslipidaemia, coagulation disorders, increased inflammation and endothelial dysfunction). • L-thyroxine substitution seems to be beneficial regarding its effect on lipidaemic profile, although mainly in patients with TSH > 10 mIU/l. • Its effect on other cardiovascular risk factors and glucose homoeostasis remains unclear. What's new • In patients with SH and TSH < 7 mIU/l, no improvement in lipidaemic profile is noticed after L-thyroxine replacement therapy. • No effect on glucose metabolism is noticed after L-thyroxine replacement therapy. • No effect on systemic inflammation and coagulation factors is noticed after thyroxine replacement therapy.
Endocrine, 2014
Several studies have shown that acromegaly is associated with increased psychological morbidity. ... more Several studies have shown that acromegaly is associated with increased psychological morbidity. However, it is not known whether this is attributed to acromegaly per se or to its chronicity as a debilitating disease affecting quality of life (QoL). The aim of this study was to assess psychological profile in acromegalics compared with those suffering from other serious chronic diseases and healthy controls. Secondary end points were QoL assessment and its association with mood disturbances. Comparative, cross-sectional study conducted in Northern Greece (2011-2012). The Greek versions of the Profile of Mood States (POMS) and AcroQoL questionnaires were used to assess psychological status and QoL, respectively. Forty acromegalics, 40 age- and sex-matched people with other chronic diseases and 80 healthy controls were included. No significant differences were identified between acromegalics and those suffering from other chronic diseases, regarding tension, anger, depression, confusion, fatigue and vigor. Compared with healthy controls, acromegalics suffered more from depression and anger, which remained significant after controlling for age, gender and marital status (p = 0.003 and p = 0.048, respectively). Negative predictors were female gender, macroadenomas and radiotherapy. AcroQoL scores were negatively associated with POMS subscales. Males had better QoL than females. Other than a negative association between AcroQoL-relationships subscale and disease duration, no association with other parameters was observed. Acromegaly has a negative impact on psychological status, which is worse than that of general population, but comparable to other chronic diseases. Mood disturbances are associated with impaired QoL, mainly in females and those with longer disease duration.
Indian Journal of Endocrinology and Metabolism, 2012
International Journal of Clinical Practice, May 12, 2011
HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific re... more HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Endocrine Abstracts, 2016
Endocrine Abstracts, 2016
The Open Cardiovascular Medicine Journal, 2014
Aims: Low 25-hydroxy-vitamin D [25(ΟΗ)D] levels have been associated with increased risk for card... more Aims: Low 25-hydroxy-vitamin D [25(ΟΗ)D] levels have been associated with increased risk for cardiovascular disease. Conflicting data exist regarding the effect of statins on [25(OH)D] levels. The aim of this study was to compare the effect of atorvastatin and rosuvastatin on 25(OH)D levels in non-diabetic patients with dyslipidaemia. Methods: This was a prospective randomized open-label study. Patients were assigned to atorvastatin 20 mg⁄day (n=28, age: 56.1±2.2 years, 22 females) or rosuvastatin 10 mg⁄day (n=24, age: 57.4±1.9 years, 20 females). Total cholesterol (TC), low- (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting plasma glucose, insulin, glycosylated haemoglobin A1c (HbA1c) and high sensitivity C-reactive protein (hsCRP) levels were measured, and homeostatic model of assessment insulin resistance (HOMA-IR) was calculated at baseline and 12 weeks post-treatment. Results: There were no within or between group significant differences in 2...
International Journal of Clinical Practice, 2011
The data presented under the header "At baseline" in page 8 refer to morbidity discovered at base... more The data presented under the header "At baseline" in page 8 refer to morbidity discovered at baseline. Because there were missing values, for further clarity, we have added the number of patients who were actually examined for each co-morbidity at presentation in p8, 2 nd paragraph, lines 5-8: "…..(data available for 84). Data on glucose homeostasis were available for 87 patients at presentation and were diagnostic for DM in 25%, for impaired glucose tolerance (IGT) in another 25%. Dyslipidemia was present in 35% (data available in 60 subjects)." 3. DA treatment: the authors should explain the abbreviation. DA stands for dopamine agonists. We have added the definition the first time it appears in the text: page 10, 2 nd paragraph, line 6.
Indian journal of endocrinology and metabolism, 2012
Endocrine Abstracts, 2013
Uploads
Papers by Despina Selalmatzidou